February 2026 Research Update

This month added two complementary pieces to the long-term management picture in IgG4-related disease: one study tracked how often relapse happened during azathioprine maintenance, and another study suggested that changes in a person’s IgG4 over time may signal relapse risk better than a single IgG4 value. Put together, the studies point to a theme that staying well can be durable for some people, but relapse remains a real possibility and may be preceded by measurable lab changes in some patients. These findings are based on observational data, so they describe patterns seen in care rather than proving what will happen for an individual. [1] [2]

In a small single-center group of 10 patients who used azathioprine after steroid induction, 7 remained in remission over long follow-up while 3 had relapse episodes during azathioprine therapy. Side effects were reported, including infections, blood count abnormalities, and elevated liver enzymes. This helps put realistic boundaries around what maintenance treatment looked like in routine practice for this small group: many stayed stable, but relapse and monitoring for side effects were part of the story. [1]

In a larger cohort of 155 patients, a single IgG4 blood level at one moment did not predict relapse, but an IgG4-Ratio (a way of looking at how IgG4 changes over time) above certain thresholds did. The study reported that a threshold above 1.6 best predicted relapse, and among people who crossed that threshold, intensified treatment after a surge was linked with a lower relapse risk in their analysis. For patients, the practical meaning is that "trend over time" may carry different information than a one-off number, although the study does not establish a universal monitoring plan. [2]

For patients and caregivers, this month’s evidence mainly adds understanding about what relapse can look like over time and what kinds of signals might appear before it. The azathioprine report suggests some people can remain in remission for years on maintenance therapy, while others relapse and some experience side effects. The IgG4-Ratio study suggests that watching how IgG4 changes may be more informative than relying on a single IgG4 level, but it remains uncertain how well this applies across different hospitals, treatments, and IgG4-RD organ patterns. [1] [2]

This month’s biology studies converged on a clearer idea that IgG4-related disease activity may be reflected by specific immune cell patterns and inflammatory pathways, but no single blood marker worked perfectly across situations. Across studies, signals involving certain T cells, a specific B cell group, and fibrosis-related pathways appeared to track with higher IgG4 levels and measures of activity. At the same time, one commonly discussed cell marker (plasmablasts) did not consistently match imaging or clinical activity in one cohort, underscoring that biomarker interpretation can be complex. [3] [4] [5]

One immune-profiling study reported higher levels of extrafollicular Tph2 cells and CD11c+CD21- B cells in blood and affected salivary glands in IgG4-RD, and these cell frequencies tracked with serum IgG4 and disease activity measures. The same report noted that glucocorticoid treatment reduced Tph2 frequencies in parallel with falling IgG4. In plain terms, this draws a more detailed map of which immune cells may be "turned up" when the disease is more active, but it is not yet a routine clinical test. [3]

A separate clinic-based study of 35 patients found that active disease was linked with higher total IgG, higher IgG4, and higher IL-5, while PET-positive disease showed a more Th1-skewed cytokine pattern along with higher eosinophils. In that same group, plasmablast levels did not consistently track with activity scores or imaging activity. For patients, this helps explain why lab results can sometimes feel inconsistent: different parts of the immune response may dominate in different people or at different times. [4]

In IgG4-related eye disease affecting the lacrimal gland, a small tissue study reported increased proteins linked to TLR8-related signaling and fibrosis, and it found higher levels of MMP7, periostin (POSTN), and CD163 in diagnosed tissue. The study also reported that "suspected" cases looked biologically similar to diagnosed cases in several pathway signals, suggesting a possible spectrum rather than a sharp dividing line in tissue patterns. This is early, tissue-based research, so it mainly informs future work on better markers or targets rather than changing current diagnosis by itself. [5]

For patients, these studies mainly matter as research that is trying to make disease activity easier to measure and explain. They support the idea that IgG4-RD involves coordinated changes in immune cells and fibrosis pathways, and that some lab patterns may align with imaging activity. What remains uncertain is which of these signals will prove reliable enough for everyday care across many centers and different organ types, especially because some markers (like plasmablasts in one study) did not neatly match symptoms or scans. [3] [4] [5]

This month’s clinical and case-based reports reinforced how widely IgG4-related disease can show up in the body, and how often it can look like other conditions at first. Across different organs, the shared pattern was that diagnosis often depended on combining imaging with tissue biopsy, because imaging alone could resemble infection, cancer, or other inflammatory diseases. The studies also highlighted that blood IgG4 can be helpful but not definitive, and that some patients who look like IgG4-RD can ultimately have a different diagnosis. [6] [7] [8] [9] [10] [11] [12]

A nationwide Japanese series described 15 patients with localized IgG4-related cholecystitis, where imaging commonly showed subepithelial gallbladder lesions and some had cystic changes that resembled adenomyomatosis. All patients had elevated serum IgG4 and other IgG4-RD lesions, and available tissue samples showed characteristic inflammation and scarring patterns. A small subset treated with glucocorticoids showed complete resolution in 1 patient and partial improvement in 3 within weeks, illustrating that some gallbladder lesions linked to IgG4-RD can improve when recognized as inflammatory rather than malignant. [6]

Several case reports showed how IgG4-RD can mimic cancer or infection on scans, particularly in the pancreas and head and neck. One patient with painless jaundice had imaging that raised concern for pancreatic cancer, but biopsy confirmed IgG4-related autoimmune pancreatitis and symptoms improved after biliary stenting and steroids. Another patient with a sinonasal mass extending into the orbit required repeated biopsies before IgG4-RD was confirmed, after which glucocorticoids plus rituximab were followed by complete remission for more than a year in that single case. [7] [13]

Other cases highlighted less typical presentations and the limits of relying on serum IgG4 alone. Isolated bilateral lower-leg fasciitis was initially mistaken for cellulitis until biopsy showed IgG4-positive inflammation and scarring, with improvement reported after steroids and mycophenolate mofetil. Another report described gastric tumor-like lesions with abundant IgG4-positive cells, but the findings did not meet full IgG4-RD criteria and there was no recurrence after endoscopic removal during 3 years of follow-up, showing that IgG4-positive staining can occur without fitting the full disease definition. [8] [12]

Two reports emphasized the importance of considering alternative diagnoses and broader context when IgG4-RD is suspected. One patient with fever and inflammation was initially evaluated for IgG4-RD and vasculitis, but was ultimately diagnosed with VEXAS syndrome after bone marrow findings and UBA1 genetic testing, showing a clear example of a mimic. Another patient had multi-organ involvement and very high serum IgG4 with IgG4-positive tissue findings that met 2019 classification criteria, illustrating the opposite situation where the full pattern across organs supported the diagnosis. [11] [10]

For patients and caregivers, this theme mainly clarifies why diagnosis can take time and why biopsy and careful review of imaging are often central when IgG4-RD is on the list. This month’s studies show both sides: some people have classic, multi-organ patterns that make IgG4-RD more recognizable, while others have localized or unusual disease that can be confused with cancer, infection, or other immune conditions. It remains uncertain how to interpret IgG4-positive cells in every organ site, because one case had IgG4-rich tissue but still did not meet full criteria, and another person who looked like IgG4-RD actually had a different disorder. [6] [7] [13] [8] [12] [11] [10]

This month’s case reports collectively showed how IgG4-related disease and related conditions can involve very different body areas, sometimes requiring specialized imaging or procedures, and often improving after immune-suppressing treatment in that individual case. The shared message was not that one approach fits everyone, but that accurate labeling of the condition (and the organ involved) shaped what was done next, from surgery to steroid treatment to other immune therapies. Because these are single-patient reports, they are best read as examples of what can happen rather than proof of what usually happens. [14] [15] [16] [17] [18] [19] [20] [21]

Two reports focused on thickening of the dura (the covering of the brain and spinal cord), showing both diagnosis and follow-up challenges. In one patient with hypertrophic pachymeningitis, 68Ga-DOTA-TATE PET/CT showed intense uptake in the same areas that looked thickened on MRI, suggesting this type of PET scan may help map disease extent or distinguish inflammation from look-alike conditions in selected situations. In another patient with biopsy-proven IgG4-related pachymeningitis, high-dose glucocorticoids were followed by improvement on MRI and a drop in serum IgG4 over 3 months. [14] [18]

Several cases described organ-specific procedures paired with immune treatment. One patient with IgG4-RD-related refractory frontal sinusitis had a complex sinus surgery with mucosal flap reconstruction and maintained sinus opening at 6 months with headache resolution. Another patient with a coronary artery pseudoaneurysm in the setting of IgG4-RD underwent bypass surgery and pseudoaneurysm ligation, followed by corticosteroids, with a favorable reported postoperative course. [15] [16]

A few reports highlighted overlap conditions, medication context, and individualized treatment choices. One man with pulmonary arterial hypertension developed IgG4-RD after long-term high-dose intravenous epoprostenol, with diagnosis made by lip biopsy and improvement reported after systemic corticosteroids and a change in prostacyclin therapy, although cause and effect could not be proven. In an 11-year-old with sickle cell disease and autoimmune pancreatitis plus autoimmune hepatitis, serum IgG4 was elevated but tissue staining was negative, and remission was reported with steroid adjustments and azathioprine. A separate report described Riedel thyroiditis found after surgery for papillary thyroid cancer, discussing possible links to IgG4-related pathways but without direct IgG4 testing in that patient. [19] [20] [21]

One additional case described recurrent eosinophilic angiocentric fibrosis causing optic nerve compression, where intravenous steroids did not lead to improvement and rituximab was used afterward. The report's published summary did not give outcome details or mention IgG4 testing, so it is not clear whether this case was part of IgG4-RD; it mainly shows that a related scarring-inflammatory condition can be difficult to control in an individual case. [17]

For patients, these cases mainly matter as real-world examples of how varied IgG4-RD and conditions that can resemble it can be, and how care often needs to be tailored to the organ involved. They add early signals that certain specialized tools, like somatostatin-receptor PET imaging for pachymeningitis, may help in selected diagnostic dilemmas, and they show that some people improve after steroids or other immune therapies in individual reports. What remains uncertain is how often these approaches help in typical patients, because case reports cannot estimate how common a presentation is or how reliably a treatment works. [14] [18] [15] [16] [19] [20] [21] [17]